

Chiara Bianca Maria Platania

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6525673/publications.pdf>

Version: 2024-02-01

50
papers

1,650
citations

236925

25
h-index

315739

38
g-index

51
all docs

51
docs citations

51
times ranked

2498
citing authors

#	ARTICLE	IF	CITATIONS
1	Dopamine D3 receptor as a new pharmacological target for the treatment of depression. <i>European Journal of Pharmacology</i> , 2013, 719, 25-33.	3.5	115
2	Retinal and circulating miRNA expression patterns in diabetic retinopathy: An in silico and in vivo approach. <i>British Journal of Pharmacology</i> , 2019, 176, 2179-2194.	5.4	104
3	Retinal and Circulating miRNAs in Age-Related Macular Degeneration: An In vivo Animal and Human Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 168.	3.5	90
4	Current drug treatments targeting dopamine D3 receptor. , 2016, 165, 164-177.		87
5	Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. <i>International Journal of Pharmaceutics</i> , 2014, 470, 133-140.	5.2	72
6	P2X7 receptor antagonism: Implications in diabetic retinopathy. <i>Biochemical Pharmacology</i> , 2017, 138, 130-139.	4.4	71
7	Nrf2 activators modulate oxidative stress responses and bioenergetic profiles of human retinal epithelial cells cultured in normal or high glucose conditions. <i>Pharmacological Research</i> , 2015, 99, 296-307.	7.1	65
8	Homology Modeling of Dopamine D2 and D3 Receptors: Molecular Dynamics Refinement and Docking Evaluation. <i>PLoS ONE</i> , 2012, 7, e44316.	2.5	62
9	Aflibercept regulates retinal inflammation elicited by high glucose via the PIGF/ERK pathway. <i>Biochemical Pharmacology</i> , 2019, 168, 341-351.	4.4	57
10	Dopamine D3 Receptor Is Necessary for Ethanol Consumption: An Approach with Buspirone. <i>Neuropsychopharmacology</i> , 2014, 39, 2017-2028.	5.4	52
11	Computational systems biology approach to identify novel pharmacological targets for diabetic retinopathy. <i>Biochemical Pharmacology</i> , 2018, 158, 13-26.	4.4	43
12	MicroRNA target prediction in glaucoma. <i>Progress in Brain Research</i> , 2015, 220, 217-240.	1.4	40
13	Fortified Extract of Red Berry, <i>Ginkgo biloba</i> , and White Willow Bark in Experimental Early Diabetic Retinopathy. <i>Journal of Diabetes Research</i> , 2013, 2013, 1-6.	2.3	39
14	TGF- β 1 prevents rat retinal insult induced by amyloid- β (1-42) oligomers. <i>European Journal of Pharmacology</i> , 2016, 787, 72-77.	3.5	39
15	Blood-retinal barrier protection against high glucose damage: The role of P2X7 receptor. <i>Biochemical Pharmacology</i> , 2019, 168, 249-258.	4.4	39
16	Effects of Novel Nitric Oxide-Releasing Molecules against Oxidative Stress on Retinal Pigmented Epithelial Cells. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-11.	4.0	37
17	Novel Therapeutics in Glaucoma Management. <i>Current Neuropharmacology</i> , 2018, 16, 978-992.	2.9	37
18	Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. <i>Biochemical Pharmacology</i> , 2020, 177, 114004.	4.4	36

#	ARTICLE	IF	CITATIONS
19	TGF- β 2 Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9558.	4.1	35
20	Topical Ocular Delivery of TGF- β 1 to the Back of the Eye: Implications in Age-Related Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2076.	4.1	34
21	Resolvin D1 Modulates the Intracellular VEGF-Related miRNAs of Retinal Photoreceptors Challenged With High Glucose. <i>Frontiers in Pharmacology</i> , 2020, 11, 235.	3.5	33
22	Stabilization of HIF-1 α in Human Retinal Endothelial Cells Modulates Expression of miRNAs and Proangiogenic Growth Factors. <i>Frontiers in Pharmacology</i> , 2020, 11, 1063.	3.5	32
23	Controversies in Glaucoma: Current Medical Treatment and Drug Development. <i>Current Pharmaceutical Design</i> , 2015, 21, 4673-4681.	1.9	32
24	Antioxidant and Osmoprotecting Activity of Taurine in Dry Eye Models. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2018, 34, 188-194.	1.4	30
25	Dopamine D3 receptor-dependent changes in alpha6 GABAA subunit expression in striatum modulate anxiety-like behaviour: Responsiveness and tolerance to diazepam. <i>European Neuropsychopharmacology</i> , 2015, 25, 1427-1436.	0.7	28
26	Novel ophthalmic formulation of myriocin: implications in retinitis pigmentosa. <i>Drug Delivery</i> , 2019, 26, 237-243.	5.7	28
27	Ocular Pharmacological Profile of Hydrocortisone in Dry Eye Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 1240.	3.5	27
28	Novel indole derivatives targeting HuR-mRNA complex to counteract high glucose damage in retinal endothelial cells. <i>Biochemical Pharmacology</i> , 2020, 175, 113908.	4.4	27
29	Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation. <i>Journal of Pharmacy and Pharmacology</i> , 2014, 66, 954-960.	2.4	25
30	Characterization of Protein-Protein Interfaces through a Protein Contact Network Approach. <i>Frontiers in Bioengineering and Biotechnology</i> , 2015, 3, 170.	4.1	20
31	Circulating miRNAs in diabetic retinopathy patients: Prognostic markers or pharmacological targets?. <i>Biochemical Pharmacology</i> , 2021, 186, 114473.	4.4	19
32	Dihydrotanshinone, a Natural Diterpenoid, Preserves Blood-Retinal Barrier Integrity via P2X7 Receptor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9305.	4.1	17
33	1 α ,25-dihydroxyvitamin D3 protects retinal ganglion cells in glaucomatous mice. <i>Journal of Neuroinflammation</i> , 2021, 18, 206.	7.2	17
34	Regulation of intraocular pressure in mice: Structural analysis of dopaminergic and serotonergic systems in response to cabergoline. <i>Biochemical Pharmacology</i> , 2013, 86, 1347-1356.	4.4	16
35	Targeting the miRNA-155/TNFSF10 network restrains inflammatory response in the retina in a mouse model of Alzheimer's disease. <i>Cell Death and Disease</i> , 2021, 12, 905.	6.3	16
36	Synthesis, in vitro and in silico studies of HO-1 inducers and lung antifibrotic agents. <i>Future Medicinal Chemistry</i> , 2019, 11, 1523-1536.	2.3	13

#	ARTICLE	IF	CITATIONS
37	Fingolimod and Diabetic Retinopathy: A Drug Repurposing Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 718902.	3.5	13
38	Molecular Dynamics Simulation Techniques as Tools in Drug Discovery and Pharmacology: A Focus on Allosteric Drugs. <i>Methods in Molecular Biology</i> , 2021, 2253, 245-254.	0.9	13
39	Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4404.	4.1	12
40	The P2X7 receptor as a new pharmacological target for retinal diseases. <i>Biochemical Pharmacology</i> , 2022, 198, 114942.	4.4	12
41	Caffeine Protects Against Retinal Inflammation. <i>Frontiers in Pharmacology</i> , 2021, 12, 824885.	3.5	10
42	Novel Heme Oxygenase-1 (HO-1) Inducers Based on Dimethyl Fumarate Structure. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9541.	4.1	9
43	Effects of protein-protein interface disruptors at the ligand of the glucocorticoid-induced tumor necrosis factor receptor-related gene (GITR). <i>Biochemical Pharmacology</i> , 2020, 178, 114110.	4.4	9
44	New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery. <i>Frontiers in Pharmacology</i> , 2020, 11, 708.	3.5	8
45	Retinal biomarkers and pharmacological targets for Hermansky-Pudlak syndrome 7. <i>Scientific Reports</i> , 2020, 10, 3972.	3.3	7
46	Effects of Vitamin D3 and Meso-Zeaxanthin on Human Retinal Pigmented Epithelial Cells in Three Integrated in vitro Paradigms of Age-Related Macular Degeneration. <i>Frontiers in Pharmacology</i> , 2021, 12, 778165.	3.5	7
47	Glucose-Impaired Corneal Re-Epithelialization Is Promoted by a Novel Derivate of Dimethyl Fumarate. <i>Antioxidants</i> , 2021, 10, 831.	5.1	6
48	Do Extracellular RNAs Provide Insight into Uveal Melanoma Biology?. <i>Cancers</i> , 2021, 13, 5919.	3.7	6
49	Editorial: Chronic Inflammation and Neurodegeneration in Retinal Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 784770.	3.5	1
50	Therapeutic Potential of Nitric Oxide Modulation in Ocular Diseases: A Focus on Novel NO-Releasing Molecules. , 2019, , 333-334.		0